These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 25875363)

  • 1. Urinary biomarkers at early ADPKD disease stage.
    Petzold K; Poster D; Krauer F; Spanaus K; Andreisek G; Nguyen-Kim TD; Pavik I; Ho TA; Serra AL; Rotar L
    PLoS One; 2015; 10(4):e0123555. PubMed ID: 25875363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors.
    Messchendorp AL; Meijer E; Visser FW; Engels GE; Kappert P; Losekoot M; Peters DJM; Gansevoort RT;
    Am J Nephrol; 2019; 50(5):375-385. PubMed ID: 31600749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis.
    Meijer E; Boertien WE; Nauta FL; Bakker SJ; van Oeveren W; Rook M; van der Jagt EJ; van Goor H; Peters DJ; Navis G; de Jong PE; Gansevoort RT
    Am J Kidney Dis; 2010 Nov; 56(5):883-95. PubMed ID: 20888104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cystatin C estimated glomerular filtration rate to assess renal function in early stages of autosomal dominant polycystic kidney disease.
    Sans L; Radosevic A; Quintian C; Montañés R; Gràcia S; Vilaplana C; Mojal S; Ballarin JA; Fernández-Llama P; Torra R; Pascual J
    PLoS One; 2017; 12(3):e0174583. PubMed ID: 28346513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in tubular biomarkers with dietary intervention and metformin in patients with autosomal dominant polycystic kidney disease: a post-hoc analysis of two clinical trials.
    Wang W; You Z; Steele CN; Gitomer B; Chonchol M; Nowak KL
    BMC Nephrol; 2024 Jun; 25(1):206. PubMed ID: 38918734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased urinary Angiotensinogen/Creatinine (AGT/Cr) ratio may be associated with reduced renal function in autosomal dominant polycystic kidney disease patients.
    Park HC; Kang AY; Jang JY; Kim H; Han M; Oh KH; Kim SH; Noh JW; Cheong HI; Hwang YH; Ahn C
    BMC Nephrol; 2015 Jun; 16():86. PubMed ID: 26092580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of urinary endothelin-1 with estimated glomerular filtration rate in autosomal dominant polycystic kidney disease: a pilot cross-sectional analysis.
    Raina R; Lou L; Berger B; Vogt B; Do AS; Cunningham R; Vasavada P; Herrmann K; Dell K; Simonson M
    BMC Nephrol; 2016 Feb; 17():22. PubMed ID: 26923419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary metabolites associate with the rate of kidney function decline in patients with autosomal dominant polycystic kidney disease.
    Dekker SEI; Verhoeven A; Soonawala D; Peters DJM; de Fijter JW; Mayboroda OA;
    PLoS One; 2020; 15(5):e0233213. PubMed ID: 32442208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KIM-1 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease: HALT-PKD Results.
    Griffin BR; You Z; Noureddine L; Gitomer B; Perrenoud L; Wang W; Chonchol M; Jalal D;
    Am J Nephrol; 2020; 51(6):473-479. PubMed ID: 32541154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The correlation between kidney volume and measured glomerular filtration rate in an Asian ADPKD population: a prospective cohort study.
    Phakdeekitcharoen B; Treesinchai W; Wibulpolprasert P; Boongird S; Klytrayong P
    BMC Nephrol; 2021 May; 22(1):178. PubMed ID: 33992075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of the Urine-to-Plasma Urea Ratio to Predict ADPKD Progression.
    Heida JE; Gansevoort RT; Messchendorp AL; Meijer E; Casteleijn NF; Boertien WE; Zittema D;
    Clin J Am Soc Nephrol; 2021 Feb; 16(2):204-212. PubMed ID: 33504546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary Angiotensinogen in addition to Imaging Classification in the Prediction of Renal Outcome in Autosomal Dominant Polycystic Kidney Disease.
    Park HC; Kim J; Cho A; Kim DH; Lee YK; Ryu H; Kim H; Oh KH; Oh YK; Hwang YH; Lee KB; Kim SW; Kim YH; Lee J; Ahn C;
    J Korean Med Sci; 2020 Jun; 35(22):e165. PubMed ID: 32508065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease.
    Kline TL; Korfiatis P; Edwards ME; Bae KT; Yu A; Chapman AB; Mrug M; Grantham JJ; Landsittel D; Bennett WM; King BF; Harris PC; Torres VE; Erickson BJ;
    Kidney Int; 2017 Nov; 92(5):1206-1216. PubMed ID: 28532709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD).
    Nakajima A; Lu Y; Kawano H; Horie S; Muto S
    Clin Exp Nephrol; 2015 Dec; 19(6):1199-205. PubMed ID: 25715868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Urinary Neutrophil Gelatinase-Associated Lipocalin for Predicting the Severity of Renal Functions in Patients With Autosomal-Dominant Polycystic Kidney Disease.
    Vareesangthip K; Vareesangthip K; Limwongse C; Reesukumal K
    Transplant Proc; 2017 Jun; 49(5):950-954. PubMed ID: 28583565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Markers of Glomerular and Tubular Damage in the Early Stage of Kidney Disease in Type 2 Diabetic Patients.
    Żyłka A; Dumnicka P; Kuśnierz-Cabala B; Gala-Błądzińska A; Ceranowicz P; Kucharz J; Ząbek-Adamska A; Maziarz B; Drożdż R; Kuźniewski M
    Mediators Inflamm; 2018; 2018():7659243. PubMed ID: 30158836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kidney volume and function in autosomal dominant polycystic kidney disease.
    Higashihara E; Nutahara K; Okegawa T; Shishido T; Tanbo M; Kobayasi K; Nitadori T
    Clin Exp Nephrol; 2014 Feb; 18(1):157-65. PubMed ID: 23864346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary renin-angiotensin markers in polycystic kidney disease.
    Salih M; Bovée DM; Roksnoer LCW; Casteleijn NF; Bakker SJL; Gansevoort RT; Zietse R; Danser AHJ; Hoorn EJ
    Am J Physiol Renal Physiol; 2017 Oct; 313(4):F874-F881. PubMed ID: 28747358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Podocyte Injury in Autosomal Dominant Polycystic Kidney Disease.
    Cebeci E; Ekinci I; Gursu M; Coskun C; Karadag S; Uzun S; Behlul A; Senel TE; Kazancioglu R; Ozturk S
    Nephron; 2019; 142(4):311-319. PubMed ID: 31117091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.